For drug makers, new 3-D control opens wealth of options

February 7, 2013

A team of scientists anchored at Yale University has demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment. They report their results in the journal Science on Feb 8.

Drug molecules interact with their targets, such as proteins or enzymes, by attaching to them in a way that neutralizes the target's undesirable effects in the body. This is sometimes called the "lock-and-key" method. The new approach offers scientists far greater control over the three-dimensional structure of a key class of , making it easier to fashion that fit their targets in the right way.

"Now we've got a lot more control over the shape and orientation of this class of , and this essentially gives us greater flexibility in creating effective drugs," said Jonathan Ellman, the Yale chemist who led the experiment.

The research reported in Science revolves around piperidines, a class of widely used in pharmaceuticals, including the familiar drugs quinine, morphine, oxycodone, Plavix, Cialis, and Aricept. Piperidines are core structures, or scaffolds, upon which —parts of the drug molecule—can be displayed for binding to a drug's targets. The scientists have shown a way to generate different piperidine derivatives by varying acid strength.

"Our research allows us to make new piperidines easily," Ellman said. "The approach has biomedical relevance because the scaffold upon which the fragments are displayed is present in many of the most important drugs."

The research is being published without patent constraints and could be used by drug developers immediately, said Ellman, who is the Eugene Higgins Professor of Chemistry and professor of pharmacology. "I believe that this is the most effective approach for rapidly translating this work into new drugs," he said.

Explore further: Cancer's next magic bullet may be magic shotgun

More information: "Proton Donor Acidity Controls Selectivity in Nonaromatic Nitrogen Heterocycle Synthesis," Science, 2013.

Related Stories

Cancer's next magic bullet may be magic shotgun

June 15, 2012

A new approach to drug design, pioneered by a group of researchers at the University of California, San Francisco (UCSF) and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that ...

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.